Maze Therapeutics, a Phase 2 biotech developing precision small molecule therapies for kidney disease and other indications, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Maze Therapeutics is developing novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups. Its most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1 (APOL1) for the treatment of patients with APOL1 kidney disease. Maze reported results for its Phase 1 trial of MZE829 in October 2024, which showed that treatment was well tolerated, and initiated a Phase 2 trial in November 2024. It expects to dose its first patient in the 1Q25, with proof of concept data expected in the 1Q26.
The South San Francisco, CA-based company was founded in 2017 and booked $168 million in license revenue for the 12 months ended September 30, 2024. It plans to list on the Nasdaq under the symbol MAZE. Maze Therapeutics filed confidentially on June 21, 2024. J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.